nach oben

Erschienen in:

01.05.2010 | Clinical Study - Patient Study

Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27^kip1

verfasst von: Jinlong Shi, Li Zhang, Aiguo Shen, Jianguo Zhang, Yuchan Wang, Yueming Zhao, Lin Zou, Qing Ke, Fei He, Ping Wang, Chun Cheng, Gongshen Shi

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Forkhead box class O 3a (FOXO3a) is an important direct target of the phosphatidylinositol 3-kinase (PI3K)/protein B(Akt) pathway, mediating signal transduction in regulating cell survival and cell-cycle progression. Recent reports have shown that FOXO3a inhibits cell-cycle progression at the G1/S transition by controlling transcription of the cyclin-dependent kinase inhibitor p27^kip1, which is frequently down-regulated in human cancers, including human glioma. In this study we investigated the status of FOXO3a expression and related signaling in human glioma in order to test its potential value as a therapeutic target for this disease. Immunohistochemistry, western blot, RT-PCR, and immunofluorescence staining analysis were performed on specimens from 70 cases of human glioma and on U87MG and T98G glioma cells. Our data showed FOXO3a expression is directly correlated with the malignant grade of glioma. More importantly, low expression of FOXO3a was associated with poor patient outcome. In vitro, FOXO3a modulated the cell cycle by transcriptional regulation of p27^kip1. Administration of the PI3K pharmacological inhibitor LY294002 abrogated this effect by regulating FOXO3a expression and subcellular localization. Our results suggested that FOXO3a may be a favorable independent prognostic indicator of glioma. Gene therapeutic approaches aimed at PI3K or at pharmacological inhibitors of PI3K to down-regulate P-FOXO3a expression could be developed for management of glioma.

Jemal A, Murray T, Ward E, Samuels A, Tiwari RC et al (2005) Cancer statistics. CA Cancer J Clin 55:10–30CrossRefPubMed

Surawicz TS, Davis F, Freels S et al (1998) Brain tumor survival: results from the national cancer data base. J Neurooncol 40:151–160CrossRefPubMed

Das A, Banik NL, Patel SJ, Ray SK (2004) Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax: Bcl-2 ratio and preventing proteolytic activities. Mol Cancer 3:36CrossRefPubMed

Choi JW, Lee MM, Kim IA, Kim JH et al (2008) The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study. J Korean Neurosurg Soc 44:222–227CrossRefPubMed

Accili D, Arden KC (2004) FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117:421–426CrossRefPubMed

Burgering BM, Kops GJ (2002) Cell cycle and death control: long live forkheads. Trends Biochem Sci 27:352–360CrossRefPubMed

Tran H, Brunet A, Griffith EC, Greenberg ME (2003) The many forks in FOXO’s road. Sci STKE 2003: RE5

Van Der Heide LP, Hoekman MF, Smidt MP (2004) The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 380:297–309CrossRef

Brunet A, Bonni A, Zigmond MJ et al (1999) Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96:857–868CrossRefPubMed

10.

Polyak K, Lee MH, Erdjument-Bromage H et al (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59–66CrossRefPubMed

11.

Toyoshima H, Hunter T (1994) p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67–74CrossRefPubMed

12.

Kirla RM, Haapasalo HK, Kalimo H, Salminen EK (2003) Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 97:644–648CrossRefPubMed

13.

Choe G, Horvath S, Cloughesy TF, Crosby K et al (2003) Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746PubMed

14.

Dijkers PF, Medema RH, Pals C, Banerji L et al (2000) Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 20:9138–9148CrossRefPubMed

15.

Nakamura N, Ramaswamy S, Vazquez F et al (2000) Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20:8969–8982CrossRefPubMed

16.

Stahl M, Dijkers PF, Kops GJ, Lens SM (2002) The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 168:5024–5031PubMed

17.

Medema RH, Kops GJ, Bos JL, Burgering BM (2000) AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404:782–787CrossRefPubMed

18.

Vogt PK, Bader AG, Kang S (2006) PI 3-kinases: hidden potentials revealed. Cell Cycle 5:946–949PubMed

19.

Zhao JJ, Roberts TM (2006) PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci STKE 2006: pe52

20.

Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606–619CrossRefPubMed

21.

Lam EW, Francis RE, Petkovic M (2006) FOXO transcription factors: key regulators of cell fate. Biochem Soc Trans 34:722–726CrossRefPubMed

22.

Kennedy SG, Wagner AJ, Conzen SD et al (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 11:701–713CrossRefPubMed

23.

Songyang Z, Baltimore D, Cantley LC et al (1997) Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci USA 94:11345–11350CrossRefPubMed

24.

Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10:262–267CrossRefPubMed

25.

Reed SI (1997) Control of the G1/S transition. Cancer Surv 29:7–23PubMed

26.

Lloyd RV, Erickson LA, Jin L et al (1999) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313–323PubMed

27.

Kops GJ, Burgering BM (1999) Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med 77:656–665CrossRefPubMed

28.

Carlsson P, Mahlapuu M (2002) Forkhead transcription factors: key players in development and metabolism. Dev Biol 250:1–23CrossRefPubMed

29.

Lehmann OJ, Sowden JC, Carlsson P et al (2003) Fox’s in development and disease. Trends Genet 19:339–344CrossRefPubMed

30.

Hu MC, Lee DF, Xia W, Golfman LS et al (2004) IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117:225–237CrossRefPubMed

31.

Burgering BM, Medema RH (2003) Decisions on life and death: FOXO forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 73:689–701CrossRefPubMed

32.

Plas DR, Thompson CB (2003) Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 278:12361–12366CrossRefPubMed

33.

Yang L, Xie S, Jamaluddin MS, Altuwaijri S et al (2005) Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 280:33558–33565CrossRefPubMed

34.

Nam S, Smith DM, Dou QP (2001) Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276:13322–13330CrossRefPubMed

35.

Essafi A, Fernandez de Mattos S et al (2005) Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 24:2317–2329CrossRefPubMed

36.

Fernandez de Mattos S, Essafi A, Soeiro I et al (2004) FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol 24:10058–10071CrossRefPubMed

37.

Alexia C, Bras M, Fallot G, Vadrot N et al (2006) Pleiotropic effects of PI-3′ kinase/Akt signaling in human hepatoma cell proliferation and drug-induced apoptosis. Ann NY Acad Sci 1090:1–17CrossRefPubMed

38.

Jin S, Pang RP, Shen JN, Huang G, Wang J, Zhou JG (2007) Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis 12:1317–1326CrossRefPubMed

39.

Hu MC, Hung MC (2005) Role of IkappaB kinase in tumorigenesis. Future Oncol 1:67–78CrossRefPubMed

Titel: Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27kip1
verfasst von: Jinlong Shi
Li Zhang
Aiguo Shen
Jianguo Zhang
Yuchan Wang
Yueming Zhao
Lin Zou
Qing Ke
Fei He
Ping Wang
Chun Cheng
Gongshen Shi
Publikationsdatum: 01.05.2010
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2010
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-009-0045-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Adjuvant Gamma Knife radiosurgery following surgical resection of brain metastases: a 9-year retrospective cohort study

Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy

The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients

Seizure risk in brain tumor patients with conversion to generic levetiracetam

The cell-cycle kinetics of craniopharyngioma and its clinical significance